Sheng-Long Ye

TL;DR: Sorafenib is effective for the treatment of advanced hepatocellular carcinoma in patients from the Asia-Pacific region, and is well tolerated.

TL;DR: GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) is a global, prospective, non‐interventional study undertaken to evaluate the safety of sorafenib in patients with unresectable HCC in real‐life practice, including Child‐Pugh B patients who were excluded from clinical trials.

TL;DR: GIDEON, a global, non‐interventional, surveillance study, aims to evaluate the safety of sorafenib in all patients with unresectable hepatocellular carcinoma under real‐life practice conditions, particularly Child‐Pugh B patients, who were not well represented in clinical trials.

TL;DR: Non‐surgical treatments include ablation, transarterial chemoembolisation and the multikinase inhibitor, sorafenib, but their effects in all patient subgroups are not known and further information is needed to optimise the use of these treatments.

TL;DR: Overall, the incidence of AEs and drug-related AEs was similar across CP subgroups, although serious AEs were more common in Child-Pugh B pts with more advanced liver dysfunction, and the average daily Sor dose was slightly higher in CP-B than CP-A pts.